To protect their business reputation, most companies invest a lot of money to make sure you can log in securely and use your account. What you need to pay attention to is whether your network is secure and visits the correct website address. Here’s the information that has been manually reviewed about ascopubs.org pediatric login :
ASCO Publications
ASCO’s publications—including the Society’s flagship publication, the Journal of Clinical Oncology—serve readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research that informs the …
Mapping Pediatric Oncology Clinical Trial … – ascopubs.org
https://ascopubs.org/doi/abs/10.1200/GO.21.00266
Feb 14, 2022 · PURPOSE The global pediatric oncology clinical research landscape, particularly in Central and South America, Africa, and Asia, which bear the highest burden of global childhood cancer cases, is less characterized in the literature. Review of how existing pediatric cancer clinical trial groups internationally have been formed and how their research goals have been …
Mapping Pediatric Oncology Clinical Trial … – ascopubs.org
https://ascopubs.org/doi/full/10.1200/GO.21.00266
Feb 14, 2022 · The Indian Pediatric Oncology Group (InPOG) was founded in 2008 to create a platform for multicenter cooperative group research across India. 120 After several years of building clinical trial infrastructure, InPOG started recruiting pediatric patients for its first collaborative trials in 2015. 120,121 A preliminary report from the InPOG HL …
https://ascopubs.org/doi/pdf/10.1200/GO.21.00266
Pediatric Clinical Trial Group Regions Represented Parent Founding Body Year Founded Collaborative Relationships Published Clinical Trials APNOS Egypt, Morocco, Algeria, Tunisia, Libya, Sudan, Nigeria, Zimbabwe, Kenya — 2019 — No Pediatric Oncology Group of East Africa Tanzania, Burundi, Rwanda, Uganda, Kenya, South Sudan, Ethiopia ———No
Phase II Trial of Inotuzumab Ozogamicin in … – ascopubs.org
https://ascopubs.org/doi/10.1200/JCO.21.01693
Jan 10, 2022 · PURPOSE Children’s Oncology Group trial AALL1621 was conducted to prospectively determine the safety and efficacy of inotuzumab ozogamicin (InO) in pediatric and adolescent patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). PATIENTS AND METHODS This single-arm phase II trial enrolled patients age 1-21 years …
Association Between Radioactive Iodine … – ascopubs.org
https://ascopubs.org/doi/full/10.1200/JCO.21.01841
Jan 19, 2022 · DOI: 10.1200/JCO.21.01841 Journal of Clinical Oncology – published online before print January 19, 2022 . PMID: 35044839
Fusion Oncogenes Are Associated With … – ascopubs.org
https://ascopubs.org/doi/10.1200/JCO.21.01861
Jan 11, 2022 · The incidence of a BRAF p.V600E mutation in pediatric patients with PTC is lower and there is a lower risk for BRAF-associated widely invasive disease with decreased radioactive iodine avidity. 5,12,13 In addition, coexisting mutations in the TERT promoter, TP53, and genes encoding effectors of the PI3K pathway (PIK3CA) are frequent in BRAF-mut …
Polygenic Ara-C Response Score Identifies Pediatric …
https://ascopubs.org/doi/10.1200/JCO.21.01422
Jan 06, 2022 · DOI: 10.1200/JCO.21.01422 Journal of Clinical Oncology – published online before print January 6, 2022 . PMID: 34990262